Spacelabs Healthcare said that the latest in the Ultraview series, the new DM3, is produced by combining the simplistic performance of a spot-check monitor with the sophistication of continuous monitoring. It can be used in any patient care environment where basic vital signs monitoring is needed.

In Spot-Check mode, the DM3 supports batch collection of basic vitals for multiple patients. Supplemental patient information, such as Pain Level, Patient Position (during NIBP), Site Check, and Caregiver ID, can also be specified by the user for inclusion in the patient’s record.

After the collection of patient vitals has been completed, the DM3 can be connected to the network to transmit the spot-check records for one or multiple patients to the hospital’s EMR system. In Monitoring mode, the DM3 provides continuous monitoring and alarm support for patients who require more vigilance. In those instances, such as following a procedure, short-term but constant monitoring may be necessary based on variable patient acuity.

The Ultraview DM3 has recently received FDA 510(k) clearance for market and sale within the US. Plans are underway to expand marketing and sales efforts into Canada, Europe, Middle East and Africa.

Nicholas Ong, group president, said: “In keeping with Spacelabs’ tradition of connecting innovation with care, we are pleased to introduce the Ultraview DM3, a versatile and cost-effective clinical solution, as well as an exciting addition to our expanding line of monitoring and diagnostic products.”

Spacelabs Healthcare, a wholly-owned subsidiary of OSI Systems, is a developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices.